* Says it plans to acquire stakes in two pharma firms via cash, share issue
* To reaffirm projected full year 2016 consolidated adjusted income from operations per share, which remains in range of $8.95 to $9.35 Source text for Eikon: [ID:(http://1.usa.gov/1TBKQua )] Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
* Says it plans to set up project company to invest $25 million in U.S. pharma firm Provision Healthcare
May 26 The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Thursday:
BRIEF-Nexvet Biopharma announces positive results from NV-02 pilot field study in cats with osteoarthritis
* Nexvet announces positive results from nv-02 pilot field study in cats with osteoarthritis
No related earnings announcements are currently scheduled within the next 7 days.